Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure
- PMID: 36036745
- DOI: 10.1093/eurheartj/ehac483
Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure
Conflict of interest statement
Conflict of interest: J.H. receives salary support from T32 training grant T32HL069749. S.D.A. receives fees from Abbott, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Occlutech, Servier, and Vifor Pharma, and grant support from Abbott and Vifor Pharma. J.B. serves as a consultant to Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Berlin Cures, Boehringer Ingelheim, Bristol-Myers Squib, CVRx, G3 Pharmaceutical, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Occlutech, Relypsa, Roche, Sanofi, SC Pharma, V-Wave Limited, and Vifor.
Comment on
-
Empagliflozin in acute myocardial infarction: the EMMY trial.Eur Heart J. 2022 Nov 1;43(41):4421-4432. doi: 10.1093/eurheartj/ehac494. Eur Heart J. 2022. PMID: 36036746 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
